Shotguns vs Lasers: Identifying barriers and facilitators to scaling-up plant molecular farming for high-value health products.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
08
2019
accepted:
18
02
2020
entrez:
21
3
2020
pubmed:
21
3
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Plant molecular farming (PMF) is a convenient and cost-effective way to produce high-value recombinant proteins that can be used in the production of a range of health products, from pharmaceutical therapeutics to cosmetic products. New plant breeding techniques (NPBTs) provide a means to enhance PMF systems more quickly and with greater precision than ever before. However, the feasibility, regulatory standing and social acceptability of both PMF and NPBTs are in question. This paper explores the perceptions of key stakeholders on two European Union (EU) Horizon 2020 programmes-Pharma-Factory and Newcotiana-towards the barriers and facilitators of PMF and NPBTs in Europe. One-on-one qualitative interviews were undertaken with N = 20 individuals involved in one or both of the two projects at 16 institutions in seven countries (Belgium, France, Germany, Italy, Israel, Spain and the UK). The findings indicate that the current EU regulatory environment and the perception of the public towards biotechnology are seen as the main barriers to scaling-up PMF and NPBTs. Competition from existing systems and the lack of plant-specific regulations likewise present challenges for PMF developing beyond its current niche. However, respondents felt that the communication of the benefits and purpose of NPBT PMF could provide a platform for improving the social acceptance of genetic modification. The importance of the media in this process was highlighted. This article also uses the multi-level perspective to explore the ways in which NPBTs are being legitimated by interested parties and the systemic factors that have shaped and are continuing to shape the development of PMF in Europe.
Identifiants
pubmed: 32196508
doi: 10.1371/journal.pone.0229952
pii: PONE-D-19-23672
pmc: PMC7083274
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0229952Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Przegl Lek. 2015;72(10):567-71
pubmed: 26946569
Curr Opin Biotechnol. 2019 Apr;56:43-47
pubmed: 30248640
Plant Biotechnol J. 2019 Feb;17(2):350-361
pubmed: 29969180
Plant Biotechnol J. 2014 Apr;12(3):300-11
pubmed: 24256218
Biotechnol J. 2007 Sep;2(9):1169-78
pubmed: 17703489
Biotechnology (N Y). 1990 Mar;8(3):217-21
pubmed: 1366404
Nat Biotechnol. 2018 Jan 10;36(1):6-7
pubmed: 29319694
Plant Biotechnol J. 2015 Oct;13(8):1013-6
pubmed: 26345276
Nature. 1989 Nov 2;342(6245):76-8
pubmed: 2509938
Plant Biotechnol J. 2010 Jun;8(5):525-8
pubmed: 20500680
Front Bioeng Biotechnol. 2018 Jun 18;6:79
pubmed: 29967764
Front Immunol. 2018 Aug 10;9:1803
pubmed: 30147687
PLoS One. 2016 Jun 17;11(6):e0157034
pubmed: 27314851
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11745-9
pubmed: 1465391
Int J Mol Sci. 2015 Dec 02;16(12):28549-65
pubmed: 26633378
PLoS Biol. 2016 May 04;14(5):e1002453
pubmed: 27144921
Biotechnol Adv. 2011 Mar-Apr;29(2):210-22
pubmed: 21115109
Front Plant Sci. 2017 Mar 27;8:403
pubmed: 28396675
Front Plant Sci. 2017 Jan 05;7:1999
pubmed: 28105036
Curr Opin Biotechnol. 2020 Feb;61:53-59
pubmed: 31751895
Trends Biotechnol. 2003 Dec;21(12):570-8
pubmed: 14624867
Trends Biotechnol. 2016 Aug;34(8):604-605
pubmed: 27266813
Plant Biotechnol J. 2013 Dec;11(9):1029-33
pubmed: 24119183
Biotechnol Adv. 2010 Mar-Apr;28(2):214-21
pubmed: 19961918
PLoS One. 2017 Sep 6;12(9):e0183213
pubmed: 28877215
Nature. 2018 Nov;563(7729):15-16
pubmed: 30377319
Transgenic Res. 2019 Apr;28(2):247-256
pubmed: 30830581
Plant J. 2014 Jun;78(5):742-52
pubmed: 24330272
Pharm Bioprocess. 2014 Dec 1;2(6):499-518
pubmed: 25621170
EMBO Rep. 2005 Jul;6(7):593-9
pubmed: 15995674
J Exp Bot. 2017 Jul 10;68(15):4009-4011
pubmed: 28922776
Biotechnol Adv. 2012 Mar-Apr;30(2):434-9
pubmed: 21856403
Trends Biotechnol. 2008 Sep;26(9):506-17
pubmed: 18676047
Biotechnol Adv. 2015 Jan-Feb;33(1):41-52
pubmed: 25536441
Plant Cell Rep. 2016 Jul;35(7):1493-506
pubmed: 27142995
EMBO Rep. 2016 Oct;17(10):1365-1369
pubmed: 27629042
Public Underst Sci. 2016 May;25(4):400-14
pubmed: 27117768
Drug Discov Today. 2019 Apr;24(4):931-932
pubmed: 30880171
J Infect Dis. 2014 Jul 15;210(2):200-8
pubmed: 24511101
Genes Nutr. 2013 May;8(3):255-70
pubmed: 23076994
Nat Biotechnol. 2011 Feb;29(2):113-4
pubmed: 21301431
Hum Vaccin. 2011 Mar;7(3):375-82
pubmed: 21368584
Trends Plant Sci. 2016 May;21(5):438-449
pubmed: 26654659
Trends Biotechnol. 2016 Jul;34(7):530-534
pubmed: 27059762
Trends Biotechnol. 2018 Nov;36(11):1100-1103
pubmed: 29807731
Curr Pharm Des. 2013;19(31):5513-30
pubmed: 23394565
Curr Pharm Des. 2013;19(31):5471-7
pubmed: 23394566
PLoS One. 2017 Apr 20;12(4):e0175643
pubmed: 28426697
Curr Opin Plant Biol. 2014 Jun;19:1-7
pubmed: 24631883
Viruses. 2015 Jul 30;7(8):4254-81
pubmed: 26264020
Annu Rev Anal Chem (Palo Alto Calif). 2016 Jun 12;9(1):271-94
pubmed: 27049632
Chem Soc Rev. 2012 Mar 21;41(6):2256-82
pubmed: 22130549
N Biotechnol. 2019 Jul 25;51:49-56
pubmed: 30779963
Expert Opin Emerg Drugs. 2005 Feb;10(1):185-218
pubmed: 15757412
Plant Cell Rep. 2004 May;22(10):711-20
pubmed: 14997337
Genome Biol. 2015 Nov 05;16:242
pubmed: 26537374
EMBO Rep. 2004 Nov;5(11):1031-4
pubmed: 15520803
Front Bioeng Biotechnol. 2019 Feb 19;7:26
pubmed: 30838207
Biotechnol Lett. 2006 Dec;28(24):1983-91
pubmed: 17080241
Nature. 2016 Apr 21;532(7599):293
pubmed: 27111611